The role of multikinase inhibitors target therapy in radioiodine-resistant differentiated thyroid cancer
https://doi.org/10.14341/ket2015225-32
Abstract
About 5-15% of patients with differentiated thyroid cancer (DTC) primary or within follow-up have had distant metastases or inoperable tumor mass that are resistant to radioiodine therapy as well as dramatically deteriorate survival prognosis. Other treatment modalities (radiotherapy, chemotherapy etc.) also ineffective. Certain expectances are associated with target therapy with multikinase inhibitors with are selectively blocking onco-kinase molecular pathways. This review is devoted to analysis of those multikinase inhibitors which have been implemented in patients with radioiodine DTC. Comparative analysis of two most perspective multikinase inhibitors (sorafenib and lenvatinib) with evaluation of efficacy and adverse effects was conducted. Both of them successfully underwent 3 rd phase of clinical trial and were recommended as treatment of choice in progressive radioiodine-resistant DTC patients.
References
1. Каприн А.Д., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2013 году. - М.: МНИОИ им. П.А. Герцена; 2015. [Kaprin AD, Starinskii VV, Petrova GV. Zlokachestvennye novoobrazovaniya v Rossii v 2013 godu. Moscow: MNIOI im. P.A. Gertsena; 2015. (In Russ).]
2. Давыдов М.И., Аксесль М.Е. Статистика злокачественных новообразований в России и странах СНГ в 2012 г. - М.: РОНЦ им. Н.Н. Блохина; 2014. [Davydov MI, Aksesl’ ME. Statistika zlokachestvennykh novoobrazovanii v Rossii i stranakh CIS v 2012 g. Moscow: Russian Cancer Research Center n.a. N.N. Blokhin; 2014. (In Russ).]
3. Eustatia-Rutten CF, Corssmit EP, Biermasz NR, et al. Survival and death causes in differentiated thyroid carcinoma. J Clin Endocrinol Metab. 2006;91(1):313-319. doi: 10.1210/jc.2005-1322.
4. Pitoia F, Bueno F, Cross G. Long-term survival and low effective cumulative radioiodine doses to achieve remission in patients with 131Iodine-avid lung metastasis from differentiated thyroid cancer. Clin Nucl Med. 2014;39(9):784-790. doi: 10.1097/RLU.0000000000000507.
5. Sciuto R, Romano L, Rea S, et al. Natural history and clinical outcome of differentiated thyroid carcinoma: a retrospective analysis of 1503 patients treated at a single institution. Ann Oncol. 2009;20(10):1728-1735. doi: 10.1093/annonc/mdp050.
6. Amin A, Badwey A, El-Fatah S. Differentiated thyroid carcinoma: an analysis of 249 patients undergoing therapy and aftercare at a single institution. Clin Nucl Med. 2014;39(2):142-146. doi: 10.1097/RLU.0000000000000324.
7. Durante C, Haddy N, Baudin E, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab. 2006;91(8):2892-2899. doi: 10.1210/jc.2005-2838.
8. Robbins RJ, Wan Q, Grewal RK, et al. Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. J Clin Endocrinol Metab. 2006;91(2):498-505. doi: 10.1210/jc.2005-1534.
9. Biermann M, Pixberg M, Riemann B, et al. Clinical outcomes of adjuvant external-beam radiotherapy for differentiated thyroid cancer - results after 874 patient-years of follow-up in the MSDS-trial. Nuklearmedizin. 2009;48(3):89-98; quiz N15. doi: 10.3413/nukmed-0221.
10. Kwon J, Wu HG, Youn YK, et al. Role of adjuvant postoperative external beam radiotherapy for well differentiated thyroid cancer. Radiat Oncol J. 2013;31(3):162-170. doi: 10.3857/roj.2013.31.3.162.
11. Ye L, Santarpia L, Gagel RF. The evolving field of tyrosine kinase inhibitors in the treatment of endocrine tumors. Endocr Rev. 2010;31(4):578-599. doi: 10.1210/er.2009-0031.
12. Sherman SI. Cytotoxic chemotherapy for differentiated thyroid carcinoma. Clin Oncol (R Coll Radiol). 2010;22(6):464-468. doi: 10.1016/j.clon.2010.03.014.
13. Matuszczyk A, Petersenn S, Bockisch A, et al. Chemotherapy with doxorubicin in progressive medullary and thyroid carcinoma of the follicular epithelium. Horm Metab Res. 2008;40(3):210-213. doi: 10.1055/s-2008-1046781.
14. Shimaoka K, Schoenfeld DA, DeWys WD, et al. A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer. 1985;56(9):2155-2160.
15. Thyoird Carcinoma (version 2.2013). NCCN Clinical Practice Guidelines in Oncology. Fort Washington, PA, USA: National Comprehensive Cancer Network; 2013.
16. Droz JP, Schlumberger M, Rougier P, et al. Chemotherapy in metastatic nonanaplastic thyroid cancer: experience at the Institut Gustave-Roussy. Tumori. 1990;76(5):480-483.
17. Kim WG, Kim EY, Kim TY, et al. Redifferentiation therapy with 13-cis retinoic acids in radioiodine-resistant thyroid cancer. Endocr J. 2009;56(1):105-112.
18. Sawka AM, Thabane L, Parlea L, et al. Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis. Thyroid. 2009;19(5):451-457. doi: 10.1089/thy.2008.0392.
19. Wang KL, Lin LY, Chen PM, Lin HD. Chronic myeloid leukemia after treatment with 131 for thyroid carcinoma. J Chin Med Assoc. 2005;68(5):230-233.
20. Klubo-Gwiezdzinska J, Van Nostrand D, Burman KD, et al. Salivary gland malignancy and radioiodine therapy for thyroid cancer. Thyroid. 2010;20(6):647-651. doi: 10.1089/thy.2009.0466.
21. Rubino C, de Vathaire F, Dottorini ME, et al. Second primary malignancies in thyroid cancer patients. Br J Cancer. 2003;89(9): 1638-1644. doi: 10.1038/sj.bjc.6601319.
22. Румянцев П.О., Фомин Д.К., Румянцева У.В. Критерии резистентности высокодифференцированного рака щитовидной железы к терапии радиоактивным йодом. // Опухоли головы и шеи. - 2014. - №3 - С. 4-9. [Rumyantsev PO, Fomin DK, Rumyantseva UV. Criteria of well-differentiated thyroid carcinoma resistance to radioiodine therapy. Opukholi golovy i shei. 2014;(3):4-9.]
23. Schlumberger M, Brose M, Elisei R, et al. Definition and management of radioactive iodine-refractory differentiated thyroid cancer. Lancet Diabetes Endocrinol. 2014;2(5):356-358. doi: 10.1016/S2213-8587(13)70215-8.
24. Brose MS, Smit J, Capdevila J, et al. Regional approaches to the management of patients with advanced, radioactive iodine-refractory differentiated thyroid carcinoma. Expert Rev Anticancer Ther. 2012;12(9):1137-1147. doi: 10.1586/era.12.96.
25. Bunone G, Vigneri P, Mariani L, et al. Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features. Am J Pathol. 1999;155(6): 1967-1976. doi: 10.1016/S0002-9440(10)65515-0.
26. Klein M, Vignaud JM, Hennequin V, et al. Increased expression of the vascular endothelial growth factor is a pejorative prognosis marker in papillary thyroid carcinoma. J Clin Endocrinol Metab. 2001;86(2):656-658. doi: 10.1210/jcem.86.2.7226.
27. Homsi J, Daud AI. Spectrum of activity and mechanism of action of VEGF/PDGF inhibitors. Cancer Control. 2007;14(3):285-294.
28. Kimura ET, Nikiforova MN, Zhu Z, et al. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 2003;63(7):1454-1457.
29. Wang Y, Hou P, Yu H, et al. High prevalence and mutual exclusivity of genetic alterations in the phosphatidylinositol-3-kinase/akt pathway in thyroid tumors. J Clin Endocrinol Metab. 2007;92(6):2387-2390. doi: 10.1210/jc.2006-2019.
30. Schlumberger M, Tahara M, Wirth LJ, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015;372(7):621-630. doi: 10.1056/NEJMoa1406470.
31. Brose MS, Nutting CM, Jarzab B, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet. 2014;384(9940):319-328. doi: 10.1016/S0140-6736(14)60421-9.
32. Wilhelm SM, Adnane L, Newell P, et al. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther. 2008;7(10):3129-3140. doi: 10.1158/1535-7163.MCT-08-0013.
33. Okamoto K, Kodama K, Takase K, et al. Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models. Cancer Lett. 2013;340(1): 97-103. doi: 10.1016/j.canlet.2013.07.007.
34. Matsui J, Yamamoto Y, Funahashi Y, et al. E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int J Cancer. 2008;122(3): 664-671. doi: 10.1002/ijc.23131.
35. Cohen EE, Rosen LS, Vokes EE, et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol. 2008;26(29):4708-4713. doi: 10.1200/JCO.2007.15.9566.
36. Leboulleux S, Bastholt L, Krause T, et al. Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial. Lancet Oncol. 2012;13(9):897-905. doi: 10.1016/S1470-2045(12)70335-2.
37. Brose MS, Cabanillas ME, Cohen EE. An open-label, multi-center phase 2 study of the BRAF inhibitor vemurafenib in patietns with metastatic or unresectable papillary thryoid cancer positive for the BRAF V600 mutation and resistant to radioactive iodine. Eur J Cancer. 2013;49(suppl 3).
38. Sherman SI, Jarzab B, Caillou B. A phase II trial of the multitargeted kinase inhibitor E7080 in advanced radioiodine (RAI)-refractory differentiated thyroid cancer (DTC). J Clin Oncol. 2011;29(suppl).
39. Sherman SI, Wirth LJ, Droz JP, et al. Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med. 2008;359(1):31-42. doi: 10.1056/NEJMoa075853.
40. Bible KC, Suman VJ, Molina JR, et al. Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. Lancet Oncol. 2010;11(10):962-972. doi: 10.1016/S1470-2045(10)70203-5.
41. Hayes DN, Lucas AS, Tanvetyanon T, et al. Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements. Clin Cancer Res. 2012;18(7):2056-2065. doi: 10.1158/1078-0432.CCR-11-0563.
42. Cabanillas ME, Waguespack SG, Bronstein Y, et al. Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience. J Clin Endocrinol Metab. 2010;95(6):2588-2595. doi: 10.1210/jc.2009-1923.
43. Gupta-Abramson V, Troxel AB, Nellore A, et al. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol. 2008;26(29):4714-4719. doi: 10.1200/JCO.2008.16.3279.
44. Hoftijzer H, Heemstra KA, Morreau H, et al. Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. Eur J Endocrinol. 2009;161(6):923-931. doi: 10.1530/EJE-09-0702.
45. Kloos RT, Ringel MD, Knopp MV, et al. Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol. 2009;27(10):1675-1684. doi: 10.1200/JCO.2008.18.2717.
46. Carr LL, Mankoff DA, Goulart BH, et al. Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res. 2010;16(21): 5260-5268. doi: 10.1158/1078-0432.CCR-10-0994.
47. Lim SM, Chang H, Yoon MJ, et al. A multicenter, phase II trial of everolimus in locally advanced or metastatic thyroid cancer of all histologic subtypes. Ann Oncol. 2013;24(12):3089-3094.
Review
For citations:
Rumyantsev P.O. The role of multikinase inhibitors target therapy in radioiodine-resistant differentiated thyroid cancer. Clinical and experimental thyroidology. 2015;11(2):25-32. (In Russ.) https://doi.org/10.14341/ket2015225-32
Views:
894
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
